On the back of a heart-helping win for the 11-year-old Repatha last fall, Amgen has continued to deepen the evidence on its PCSK9 inhibitor’s ability to cut cardiovascular risks in many patients. But ...

Amgen announced new findings showing Repatha (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein ...

Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 Trial Separate ...

Repatha’s active ingredient, evolocumab, is a human monoclonal IgG2 that blocks an important protein in the body. Liver cells have specific receptors (“catchers”) on their surface. Their job is to ...

Amgen delivered Q2 2026 revenues exceeding $10 billion, up 10% YoY, with 22 products posting double-digit sales growth and six key growth drivers rising 26% YoY to comprise nearly 70% of product sales ...

Please provide your email address to receive an email when new articles are posted on . Early evolocumab prior to PCI for acute MI helped patients meet LDL goals by 1 year. Early initiation did not ...

Over the past several days, two major developments have emerged in the world of cholesterol-lowering therapies—specifically concerning the heavy-hitters known as PCSK9 inhibitors. In this letter, I’d ...